HMPL A 580
Alternative Names: HMPL-A580Latest Information Update: 20 Apr 2026
At a glance
- Originator HUTCHMED
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 09 Apr 2026 Interim pharmacokinetics and pharmacodynamics data from preclinical trials in Solid tumours released by HUTCHMED
- 04 Mar 2026 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (Parenteral) (NCT07396584)
- 09 Feb 2026 Hutchmed plans a phase I/II trial for Solid tumours (Inoperable / Unresectable, Late-stage disease, Metastatic disease) in China in March 2026 (NCT07396584)